Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Molecular Cancer Therapeutics
|
April 29, 2025
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
Anupong Tangpeerachaikul, Scot Mente, Joe Magrino, et al.
Journal of the American Chemical Society
|
December 20, 2011
Diels-Alder cycloaddition for fluorophore targeting to specific proteins inside living cells
Daniel S Liu, Anupong Tangpeerachaikul, Ramajeyam Selvaraj, et al.
Cell Reports
|
April 7, 2016
Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics
Zachary C Poss, Christopher C Ebmeier, Aaron T Odell, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Nature
|
September 30, 2015
Mediator kinase inhibition further activates super-enhancer-associated genes in AML
Henry E Pelish, Brian B Liau, Ioana I Nitulescu, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Molecular Cancer Therapeutics
|
April 29, 2025
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
Anupong Tangpeerachaikul, Scot Mente, Joe Magrino, et al.
Journal of the American Chemical Society
|
December 20, 2011
Diels-Alder cycloaddition for fluorophore targeting to specific proteins inside living cells
Daniel S Liu, Anupong Tangpeerachaikul, Ramajeyam Selvaraj, et al.
Cell Reports
|
April 7, 2016
Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics
Zachary C Poss, Christopher C Ebmeier, Aaron T Odell, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Nature
|
September 30, 2015
Mediator kinase inhibition further activates super-enhancer-associated genes in AML
Henry E Pelish, Brian B Liau, Ioana I Nitulescu, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Page
of 1